Bo app iconBo
Reference

GLP-1 & peptide half-life chart

By Melvin Morina · Updated 2026-07-27

The short answer: injectable and oral semaglutide have the longest half-life of the approved GLP-1 medications at about 1 week. Tirzepatide and dulaglutide sit near 5 days, liraglutide at about 13 hours, and immediate-release exenatide at about 2.4 hours. A dose is considered practically cleared after five half-lives, so roughly 5 weeks for semaglutide and about 25 days for tirzepatide.

The chart

CompoundClassHalf-lifeTime to peakTypical cadencePractically cleared afterEvidence
Tirzepatide
Mounjaro, Zepbound
GLP-1 / GIP dual agonist 5 days (120 hours) 24 hours once weekly 25 days (600 hours) FDA / published
Semaglutide (injectable)
Ozempic, Wegovy
GLP-1 receptor agonist 7 days (168 hours) 2 days (48 hours) once weekly 35 days (840 hours) FDA / published
Semaglutide (oral)
Rybelsus
GLP-1 receptor agonist 7 days (168 hours) 1.5 hours once daily 35 days (840 hours) FDA / published
Liraglutide
Victoza, Saxenda
GLP-1 receptor agonist 13 hours 10 hours once daily 2.7 days (65 hours) FDA / published
Dulaglutide
Trulicity
GLP-1 receptor agonist 5 days (120 hours) 2 days (48 hours) once weekly 25 days (600 hours) FDA / published
Exenatide (immediate release)
Byetta
GLP-1 receptor agonist 2.4 hours 2.1 hours twice daily 12 hours FDA / published
Retatrutide
investigational (LY3437943)
GLP-1 / GIP / glucagon triple agonist 6 days (144 hours) 24 hours once weekly (trial protocols) 30 days (720 hours) FDA / published
Survodutide
investigational (BI 456906)
GLP-1 / glucagon dual agonist 6 days (144 hours) 24 hours once weekly (trial protocols) 30 days (720 hours) FDA / published
Cagrilintide
investigational (part of CagriSema)
long-acting amylin analogue 7.5 days (180 hours) 24 hours once weekly (trial protocols) 37.5 days (900 hours) FDA / published
Orforglipron
Foundayo
oral non-peptide GLP-1 agonist 40 hours 5 hours once daily 8.3 days (200 hours) FDA / published
Tesamorelin
Egrifta
growth hormone releasing hormone analogue 30 minutes 15 minutes once daily 3 hours FDA / published
PT-141 (Bremelanotide)
Vyleesi
melanocortin receptor agonist 2.7 hours 1 hours as needed 14 hours FDA / published
MK-677 (Ibutamoren)
not FDA approved
oral growth hormone secretagogue 24 hours 1 hours once daily 5 days (120 hours) FDA / published
CJC-1295 (with DAC)
not FDA approved
GHRH analogue 7 days (168 hours) 24 hours weekly to twice weekly 35 days (840 hours) limited data
Ipamorelin
not FDA approved
growth hormone secretagogue 2 hours 30 minutes daily protocols vary 10 hours limited data
BPC-157
not FDA approved
synthetic pentadecapeptide 4 hours 1 hours daily protocols vary 20 hours limited data
TB-500 (Thymosin β4)
not FDA approved
peptide fragment 6 hours 2 hours weekly protocols vary 30 hours limited data
Sermorelin
Geref (discontinued)
GHRH analogue 12 minutes 12 minutes daily protocols vary 1 hours FDA / published
GHK-Cu
not FDA approved
copper tripeptide 1 hours 30 minutes protocols vary 5 hours limited data
MOTS-c
not FDA approved
mitochondrial-derived peptide 3 hours 1 hours protocols vary 15 hours limited data
NAD+
not FDA approved
coenzyme 2 hours 30 minutes protocols vary 10 hours limited data
Epitalon
not FDA approved
synthetic tetrapeptide 1 hours 30 minutes short courses in most protocols 5 hours limited data
GHRP-2
not FDA approved
growth hormone secretagogue 30 minutes 15 minutes daily protocols vary 3 hours limited data
GHRP-6
not FDA approved
growth hormone secretagogue 18 minutes 12 minutes daily protocols vary 2 hours limited data
Hexarelin
not FDA approved
growth hormone secretagogue 54 minutes 18 minutes daily protocols vary 5 hours limited data
HGH Fragment 176-191
not FDA approved
growth hormone fragment 30 minutes 15 minutes daily protocols vary 3 hours limited data
Thymosin Alpha-1
Zadaxin (approved in some countries)
immune-modulating peptide 2 hours 1 hours protocols vary 10 hours limited data
KPV
not FDA approved
alpha-MSH tripeptide fragment 1 hours 30 minutes protocols vary 5 hours limited data
SS-31 (Elamipretide)
investigational
mitochondria-targeting peptide 3 hours 1 hours daily in trial protocols 15 hours limited data
Semax
not FDA approved
ACTH-derived peptide 30 minutes 15 minutes daily protocols vary 3 hours limited data
Selank
not FDA approved
tuftsin-derived peptide 30 minutes 15 minutes daily protocols vary 3 hours limited data
DSIP
not FDA approved
delta sleep-inducing peptide 15 minutes 12 minutes protocols vary 1 hours limited data
AOD-9604
not FDA approved
growth hormone fragment 30 minutes 30 minutes daily protocols vary 3 hours limited data
Tesofensine
investigational
monoamine reuptake inhibitor 9.2 days (220 hours) 5 hours once daily in trial protocols 45.8 days (1100 hours) limited data
5-Amino-1MQ
not FDA approved
small-molecule NNMT inhibitor 4 hours 1 hours daily protocols vary 20 hours limited data
Kisspeptin
not FDA approved
reproductive hormone peptide 30 minutes 15 minutes protocols vary 3 hours limited data
Oxytocin
Pitocin (injectable, clinical use)
neuropeptide hormone 9 minutes 9 minutes as needed 1 hours limited data
Melanotan II
not FDA approved
melanocortin agonist 1 hours 1 hours protocols vary 5 hours limited data

How to read it

A half-life is the time it takes for half of what is in your body to be eliminated. It compounds: after one half-life about 50% remains, after two about 25%, after five about 3%. That five half-life mark is the convention behind the "practically cleared" column, and it is also roughly when levels stop climbing on a repeating schedule, which is why steady state on weekly semaglutide takes 4 to 5 weeks.

Time to peak is the other half of the picture. Semaglutide peaks 1 to 3 days after the injection, not within hours, so side effects that show up two days later are not a coincidence.

Sources

What this does not tell you

Where the numbers come from

These are the same constants Bo's estimated-levels feature uses to draw your personal curve. The app takes your actual logged doses and models what is still in your system between shots.

See your own curve in Bo →

Educational information only. Bo is a tracking app, not a medical device, and nothing here is medical advice, a dosing recommendation, or a substitute for your prescriber. Half-lives are population averages from the sources cited on each row; individual clearance varies with body weight, kidney and liver function, and other medication.